Work

Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.4_suppl.268

Authors: Eric Van Cutsem, Ken Kato, Jaffer A. Ajani, Lin Shen, Tianyu Xia, Ningning Ding, Lin Zhan, Gisoo Barnes, Sung-Bae Kim

Institutions: KU Leuven, National Cancer Center Hospital, The University of Texas MD Anderson Cancer Center, Peking University Cancer Hospital, BeiGene (China), Asan Medical Center, University of Ulsan

Language: English

Topic: Esophageal Cancer Research and Treatment

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: BeiGene

OpenAlex ID: W4205957475

Cites:

Cited by: 1

Related to: 10